drugset / Trial / NCT02170935

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

NCT02170935

Phase 2 Completed 62 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To determine the PK profile of a single dose 150 mg BIBR 1048, oral capsule, administered 1-3 hours post surgery in hip replacement patients.

Timeline

Start
2002-04
Primary completion
2002-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral